PurpleLab®, a leading health tech company specializing in real-world data and medical claims insights, and Payerset, the industry leader in enterprise price transparency data, announced today a strategic partnership to launch a trusted price intelligence solution suite, setting a new standard in healthcare intelligence.  This collaboration empowers healthcare organizations with unparalleled accuracy and actionable insights,…

The research is clear: Data drives better health outcomes.  Data has the power to transform how healthcare is delivered and guide organizations toward more patient-centered, value-driven care. Even though data is abundant, it’s often siloed or delivered in disparate data sets, and companies commonly lack the necessary resources to turn the data into insights.   Making…

Join PurpleLab and XO Health with Fierce Healthcare for an engaging discussion that melds data analytics and setting up for success with a value-based care model. The shift to a value-based care model has been a topic across the healthcare ecosystem for years now- but what will actually make that shift possible for payers and…

A recent survey from Mercer highlighted a growing trend among large employers- the search for alternative health plan options to address rising healthcare costs. The survey focused on a number of the most important factors for employers looking to increase the potential for cost savings while maintaining a competitive benefits package – designing high-performance networks…

PurpleLab® is driven by a singular goal – to provide healthcare organizations with robust and accessible real-world data (RWD) and real-world evidence (RWE) to solve conventional and emerging challenges, including tackling medication adherence. According to the FDA[1], real-world evidence (RWE) is defined as “the clinical evidence that looks at the usage and potential benefits or…

The fact that healthcare organizations need to improve care outcomes is undeniably undisputed. To succeed, health plan leaders need to acknowledge that medical care is estimated to account for only 10% to 20% of the modifiable contributors to healthy outcomes for a population. The other 80% to 90% emanates from social determinants of health (SDOH),…

Glucagon-like peptide-1 (GLP-1) agonists are a class of medications frequently used to treat type 2 diabetes mellitus (T2DM) and obesity.[1] This class of medications assists in lowering blood sugar levels and promotes weight loss. In addition to treating diabetics, these medications are also used to treat obesity in diabetics as well as non-diabetics.   GLP-1 drugs…

The COVID-19 pandemic underscored the necessity for healthcare organizations to adapt swiftly. This was particularly evident with the rapid adoption of telehealth. For instance, in the first quarter of 2020, telehealth visits surged by 50% compared to 2019. As COVID-19 becomes endemic, healthcare leaders face crucial decisions on the strategic use of telehealth versus in-person…

Healthcare today is evolving into precision medicine, or what the FDA refers to as personalized medicine.  To stay competitive in the constantly shifting healthcare landscape, organizations across the healthcare ecosystem must embrace this targeted approach and leverage the tools needed to make safe decisions for their patients or populations. By unlocking insights provided from advanced…